Recombinant tissue plasminogen activator (rt-PA) is the first-line drug for revascularization in acute cerebral infarction (ACI) treatment. In this study, an improved rat embolic middle cerebral artery occlusion model for ischaemic stroke was used and the rats were killed on the first, third and seventh day after model establishment.
revascularization in ACI treatment. 3 However, because of the limitation of a 4.5 hours thrombolysis time window, 4 most patients do not have the opportunity to receive such therapy. Therefore, effective measures in the treatment of acute ischaemic stroke are needed.
In recent years, it has been reported that the thrombolysis of ACI patients could be performed 6 hours after ACI. 5 Recent study demonstrated that thrombolytic therapy 3-9 hours after ACI could dramatically improve magnetic resonance imaging or computerized tomography results as well as clinical outcome. 6 However, the mechanism of thrombolytic therapy within a broadened therapeutic window is less obvious.
Neovascularization is a key player in ischaemic neural survival after ACI, 7 which is critical for the recovery of learning and memory abilities and for improved prognosis. Ischaemia and reperfusion can lead to a significant increase in free radicals and lipid peroxidation, thereby exacerbating brain damage. [8] [9] [10] [11] [12] The excessive release of nitric oxide (NO), an active gas free radical, could lead to neuron damage. 13 Malondialdehyde (MDA), the degradation product of lipid peroxidation, also causes direct damage to the brain. 14 Superoxide dismutase (SOD), a critical antioxidant enzyme in brain tissues, plays an important role in cerebral protection by eliminating excessive intracellular free radicals. 15 Therefore, these molecules might be key regulators implicated in the effects of rt-PA on ACI.
In this study, we used an improved rat embolic middle cerebral artery occlusion (MCAO) model to study the effects of thrombolytic therapy with rt-PA 6 hours after MCAO on infarct volume, microvascular density (MVD), caspase-3, nitric oxide , nitric-oxide synthase (NOS), MDA and SOD in the ischaemic region after ACI in an aim to uncover the underlying mechanism of thrombolytic therapy within a broadened therapeutic window and thus to provide a reliable theory basis for the clinical treatment of ACI. : 0-no obvious neurological function deficit; 1-mild degree of neurological dysfunction (i.e. when raising the rat by its tail, the contralateral forelimb cannot be fully extended); 2-moderate degree of focal neurological dysfunction (i.e. rotate to the right when walking); 3-severe degree of focal neurological dysfunction (i.e. dump to the right when walking); 4-unable to walk or in coma.
| MATERIALS AND METHODS

| Animals
Rats showing a score of 1-3 were considered to be infarcted.
| 2,3,5-triphenyl tetrazolium chloride staining
Six rats from each of above three groups were randomly selected on the first, third, and seventh day after model establishment. The rats were deeply anaesthetized and killed. The brains were rapidly removed, coronally sectioned at 2 mm, and stained with 2% 2,3,5-triphenyl tetrazolium chloride (Sigma, San Louis, MO, USA) in 0.9% saline for 30 minutes at 37°C in darkness. The slices were fixed in 10% neutral formalin overnight, and pictures were then taken using a digital camera. Image analysis was performed with Image J 
| Determination of nitric oxide and MDA contents and iNOS and SOD activities
Six rats from each of above three groups were randomly selected on the first, third and seventh day after model establishment. The animals were killed, and the brains were rapidly removed. The infarctside cortexes were rapidly frozen in liquid nitrogen and then stored at −80°C. The cortex tissue samples were homogenized in cold saline to make 10% homogenates. They were then centrifuged at 1248 g, and the supernatants were collected and stored at −80°C. Nitric oxide and MDA contents and iNOS and SOD activities were measured according to the manufacturer's instructions using the nitric oxide assay kit (A013-2; Nanjing Jiancheng Biology Engineering Institute, Nanjing, China), MDA assay kit (TBA method) (A003-1; Nanjing Jiancheng Biology Engineering Institute), NOS typed assay kit (Colormetric method) (A014-1-1; Nanjing Jiancheng Biology Engineering Institute), and SOD assay kit (WST-1 method) (A001-3; Nanjing Jiancheng Biology Engineering Institute), respectively.
| Statistical analysis
All the statistical analyses were performed with SPSS. The data in accordance with normal distribution and homogeneity of variance were presented as mean ± SD. Data between the groups were analysed by one-way analysis of variance, followed by Fisher's protected least significant difference post-hoc tests. Statistically significant differences were defined as P < 0.05. 0.65 ± 0.013% vs 0.92 ± 0.040% on the 3rd day; 0.75 ± 0.024% vs 0.93 ± 0.014% on the 7th day; all P < 0.05) (Figure 1 ).
| Thrombolysis increased the MVD after the MCAO
There were no changes in the MVD in the sham group at any timepoint. The MVD expression in the infarction groups, especially the thrombolytic group, was significantly elevated at every time-point (P < 0.05). Furthermore, the MVD expression was significantly higher in the thrombolytic group than that in the conventional group at all time-points (P < 0.05), especially on the 7th day (P < 0.01) (Figure 2 ). One day after the MACO, the expressions of nNOS and caspase-3 in the ischaemic region were enhanced in the conventional group compared with that of the sham group (P < 0.05). Furthermore, their expression was decreased in the thrombolytic group compared with the conventional group (P < 0.05). (Figure 3 ).
| Thrombolysis decreased the free radical activities and increased SOD activities after the MCAO
Nitric oxide and MDA contents and iNOS activities were potently increased in the cortex of the infarct side relative to the sham group at all time-points (P < 0.05) and they were significantly decreased by thrombolytic treatment compared with the conventional group (P < 0.05). In contrast, the SOD activities were decreased in the cortex of the infarct side relative to the sham group at all time-points (P < 0.05), and they were dramatically increased in the thrombolytic group compared with the conventional group (P < 0.05). (Figures 4-7) .
| DISCUSSION
Clinical practice has proved that the early thrombolysis of ACI could dramatically improve the prognoses and life quality of patients. At present, the intravenous infusion of rt-PA within 3 h is the most efficient therapy for ACI. 22 However, the use of rt-PA is limited by its narrow therapeutic window. Therefore, the extent to which more patients can benefit from thrombolytic therapy remains to be studied. A recent study demonstrated that the thrombolytic therapy 3-9 hours after ACI could significantly improve the clinical outcome of patients 6 ; however, the underlying mechanism is largely unknown. In our study, we used an improved rat embolic MCAO model and found that rt-PA treatment 6 hours after ACI could significantly decrease infarct volume, which was consistent with previous studies. Neovascularization is a key player in ischaemic neural survival after ACI, 7 which is critical for promoting the recovery of learning and memory abilities and for improving prognosis. The improvement of cerebral blood flow is directly related to the extent of microangiogenesis. It has been reported that ischaemia could induce VEGF expression in macrophages, astrocytes and neurons to promote neovascularization, and thus increase the oxygen and blood supply for infarct periphery and reduce the infarct size. 23, 24 Consistent with these findings, our study showed that the MVD was significantly enhanced after the MCAO, especially in the thrombolytic group. The MVD in the thrombolytic group was significantly higher than that in the conventional group at every time-point (P < 0.05), especially on the seventh day (P < 0.05). Taken together, these results indicate that as the duration of hypoxia in the ischaemic region is extended, the MVD is increased as a compensatory result and is further promoted by thrombolysis.
In cerebral ischaemia-reperfusion injury, oxidative stress is a major mechanism that aggravates the brain damage. [8] [9] [10] Ischaemia and reperfusion can lead to a surge in free radicals, and the biosynthesis of nitric oxide is a key player in the pathophysiological response. 13 Nitric oxide, synthesized by NOS from L-arginine, is a very active gas free radical. Three types of NOS in biological organisms have been identified: nNOS, endothelial NOS (eNOS) and iNOS.
Nitric oxide plays an important role in message transmission and neuroprotection in the central nervous system, but its excessive release could lead to neuron damage. The neurotoxicity of nitric oxide results mainly from its reaction with oxygen free radicals, thus producing ONOO-, NO2· and OH·. In addition, nNOS-derived endogenous nitric oxide has also been reported to play a detrimental role in the process of cerebral ischaemia-reperfusion. 25 In the present study, compared with the sham group, all of nitric oxide contents and NOS expression and activities were significantly increased in the infarct-side cortexes at all time-points (P < 0.05), and they were significantly decreased by thrombolytic treatment compared with the conventional group (P < 0.05), indicating that thrombolysis with rt-PA 6 hours after ACI still has clinical significance. A significant finding is that no increase in mortality was found in elderly patients with thrombolytic treatment 6 hours after stroke. 26, 27 Taken together, these results suggest that thrombolysis 6 hours after ACI could suppress nitric oxide-induced oxidative stress injury and neurotoxicity to improve patient outcome.
In addition, ACI-reperfusion leads to lipid peroxidation. 11, 12 MDA, the degradation product and the index of lipid peroxidation, has a very strong biological toxicity and causes direct damage to thebrain. 14 SOD, a critical antioxidant enzyme in brain tissues, plays an important role in cerebral protection by eliminating excessive intracellular free radicals. 15 Our results showed that the MDA contents and SOD activities were significantly decreased and increased, respectively, in the thrombolytic group at all time-points compared with the conventional group (P < 0.05). These results further support our hypothesis that thrombolysis within 6 hours after ACI could suppress oxidative stress injury and neurotoxicity to improve patient outcome.
Cerebral ischaemia was first reported to cause neural apoptosis in 1990 28 ; since then, numerous studies have been conducted to explore the underlying mechanisms and therapeutic treatments.
Recent studies have shown that cell apoptosis is a crucial part of cerebral ischaemia and a major mechanism responsible for secondary brain damage after cerebral ischaemia. 29 Cerebral ischaemia induces a rapid death in the cells of the ischaemic central region, and a delayed death in the cells of the ischaemic penumbra region by F I G U R E 5 Thrombolysis decreased nitric-oxide activities after MCAO. Quantification of iNOS activities in the sham group, conventional group and thrombolytic group. * indicates P < 0.05
Thrombolysis decreased malondialdehyde (MDA) contents after MCAO. Quantification of MDA contents in the sham group, conventional group and thrombolytic group. * indicates P < 0.05
Thrombolysis increased superoxide dismutase (SOD) activities after MCAO. Quantification of SOD activities in the sham group, conventional group, and thrombolytic group. * indicates P < 0.05 causing cell apoptosis. 30 Cell apoptosis after cerebral ischaemiareperfusion results from many factors. The activation of caspase-3 could cause multiple gene changes that degrade and deactivate key proteins of cytoplasm, the nucleus, and the cytoskeleton, leading to irreversible cell apoptosis. Our findings showed that caspase-3 was activated in infarction groups, and its expression was decreased in the thrombolytic group compared with in the conventional group (P < 0.05), indicating that thrombolysis within 6 hours after ACI could suppress apoptotic molecule expression to alleviate cell apoptosis, which was consistent with the previous studies showing the beneficial role of rt-PA in the control of neuronal death following stroke. 31, 32 Acute cerebral infarction patients receiving thrombolytic treatment are at risk of some complications, including neural and vascular cell death, damage to the blood-brain barrier, and intracerebral haemorrhage. Intracerebral haemorrhage is the most dangerous complication of thrombolysis, and its morbidity varies from 5% to 10%. 33 In our study, the morbidity of intracerebral haemorrhage was 8.3%
in the thrombolytic group, indicating that there was no significant difference when compared with previous studies.
There are several issues that need to be addressed. First, despite the present study and some clinical studies have suggested the efficacy and safety of thrombolysis beyond the therapeutic window of 4.5 hours, 34 no change has been made in the officially approved therapeutic window. In any case, it is still believed that the earlier the treatment the larger the treatment benefits. Furthermore, some recent clinical trials have shown the efficacy and safety of endovascular treatment as a bridging therapy of thrombolysis in the treatment of acute stroke. 35, 36 Therefore, future studies on clarifying the underlying mechanisms behind the effect of reperfusion/revascularization therapy on ACI should also take into account the thrombolysis treatment combined with endovascular therapy. Finally, there are many different experimental models of cerebral ischaemia. 37 Because of the simplicity of the model, one model is insufficient to mimic all the phenotypes of clinical patients. Therefore, it would be interesting to perform the same analyses of this study using different experimental models of cerebral ischaemia.
In conclusion, thrombolytic therapy with rt-PA within a broadened therapeutic window (6 hours) could significantly decrease the infarct volume after ACI, possibly by increasing the MVD, by decreasing the apoptotic molecule expression, and by decreasing free radical activities and enhancing SOD activities to alleviate the oxidative stress response in the ischaemic region. These findings provide a reliable theory basis for the clinical treatment of ACI with thrombolytic therapy within a broadened therapeutic window.
